T1	Participants 953 995	Patients were followed until the end of CT
T2	Participants 1338 1411	Two patients experienced VTE several days after discontinuing study drug.
T3	Participants 1412 1561	Women on dalteparin had lower levels of D-dimer and thrombin-antithrombin, and higher levels of tissue factor pathway inhibitor, relative to baseline
T4	Participants 1061 1119	Seventy-seven women were evaluable for the primary outcome
